Hussain et al., 2017 - Google Patents
Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degenerationHussain et al., 2017
View PDF- Document ID
- 4983999779533689151
- Author
- Hussain R
- Ciulla T
- Publication year
- Publication venue
- Expert opinion on emerging drugs
External Links
Snippet
Introduction: Evolving anti-vascular endothelial growth factor (VEGF) treatments for neovascular age-related macular degeneration (nAMD) include long acting agents, combination strategies involving new pathways, topical agents, sustained-release, and …
- 206010064930 Age-related macular degeneration 0 title abstract description 124
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hussain et al. | Emerging vascular endothelial growth factor antagonists to treat neovascular age-related macular degeneration | |
| Al-Khersan et al. | Innovative therapies for neovascular age-related macular degeneration | |
| Hussain et al. | Vascular endothelial growth factor antagonists: promising players in the treatment of neovascular age-related macular degeneration | |
| Nicolò et al. | Faricimab: an investigational agent targeting the Tie-2/angiopoietin pathway and VEGF-A for the treatment of retinal diseases | |
| Edington et al. | Pharmacokinetics of intravitreal anti-VEGF drugs in vitrectomized versus non-vitrectomized eyes | |
| Zhao et al. | The role of anti-vascular endothelial growth factor (anti-VEGF) in the management of proliferative diabetic retinopathy | |
| Semeraro et al. | Aflibercept in wet AMD: specific role and optimal use | |
| Tan et al. | Neovascular age-related macular degeneration (nAMD): a review of emerging treatment options | |
| Fong et al. | Long-term effectiveness of ranibizumab for age-related macular degeneration and diabetic macular edema | |
| Stewart | A review of ranibizumab for the treatment of diabetic retinopathy | |
| Kovach et al. | Anti‐VEGF treatment strategies for wet AMD | |
| Arepalli et al. | Pipeline therapies for neovascular age related macular degeneration | |
| Lang | Diabetic macular edema | |
| Do et al. | The DA VINCI Study: phase 2 primary results of VEGF Trap-Eye in patients with diabetic macular edema | |
| Dixon et al. | VEGF Trap-Eye for the treatment of neovascular age-related macular degeneration | |
| Dervenis et al. | Ranibizumab in the treatment of diabetic macular edema: a review of the current status, unmet needs, and emerging challenges | |
| Thomas et al. | Comparative effectiveness of aflibercept for the treatment of patients with neovascular age-related macular degeneration | |
| Veritti et al. | Neovascular age-related macular degeneration | |
| Smith et al. | Emerging treatments for wet age-related macular degeneration | |
| Agarwal et al. | Management of neovascular age-related macular degeneration: current state-of-the-art care for optimizing visual outcomes and therapies in development | |
| Ferro Desideri et al. | Clinical efficacy and safety of ranibizumab in the treatment of wet age-related macular degeneration | |
| Bandello et al. | Evidence for anti-VEGF treatment of diabetic macular edema | |
| Wolf et al. | Disease progression pathways of wet AMD: opportunities for new target discovery | |
| García-Layana et al. | Treatment of exudative age-related macular degeneration: focus on aflibercept | |
| Ferro Desideri et al. | The emerging role of the Angiopoietin-Tie pathway as therapeutic target for treating retinal diseases |